Open AccessFosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
Author(s) -
Sondus Alkhazraji,
Teclegiorgis Gebremariam,
Abdullah Alqarihi,
Ying Gu,
Zeinab Mamouei,
Shakti Singh,
Nathan P. Wiederhold,
Karen Joy Shaw,
Ashraf S. Ibrahim
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01735-19
Subject(s) - fusariosis , biology , microbiology and biotechnology , prodrug , voriconazole , immunology , fusarium , antifungal , pharmacology , horticulture
There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium . Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of glycosylphosphatidylinositol-anchored mannoproteins in fungi. We evaluated the in vitro activity of MGX and the efficacy of the prodrug fosmanogepix (APX001) in immunosuppressed murine models of hematogenously disseminated fusariosis and pulmonary scedosporiosis.